Medpace Holdings Net Income Over Time
| MEDP Stock | USD 444.13 15.95 3.73% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Medpace Holdings Performance and Medpace Holdings Correlation. Can Life Sciences Tools & Services industry sustain growth momentum? Does Medpace have expansion opportunities? Factors like these will boost the valuation of Medpace Holdings. Expected growth trajectory for Medpace significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Medpace Holdings demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 0.269 | Earnings Share 15.28 | Revenue Per Share | Quarterly Revenue Growth 0.32 | Return On Assets |
Understanding Medpace Holdings requires distinguishing between market price and book value, where the latter reflects Medpace's accounting equity. The concept of intrinsic value - what Medpace Holdings' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Medpace Holdings' price substantially above or below its fundamental value.
Understanding that Medpace Holdings' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Medpace Holdings represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Medpace Holdings' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Medpace Holdings and related stocks such as Illumina, ICON PLC, and Hologic Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ILMN | (5.5 M) | 86.6 M | 151.3 M | 125.3 M | 353.4 M | 461.6 M | 462.6 M | 726 M | 826 M | 1 B | 656 M | 762 M | (4.4 B) | (1.2 B) | (1.2 B) | 850 M | 892.5 M |
| ICLR | 3.9 M | 22.9 M | 55.4 M | 102.8 M | 172.5 M | 239.5 M | 262.2 M | 281.5 M | 322.8 M | 374 M | 327.8 M | 153.2 M | 505.3 M | 612.3 M | 791.5 M | 910.2 M | 955.7 M |
| HOLX | 1.4 M | (73.6 M) | (1.2 B) | 17.3 M | 131.6 M | 330.8 M | 755.5 M | (111.3 M) | (40.2 M) | 1.1 B | 1.9 B | 1.3 B | 456 M | 789.5 M | 565.7 M | 650.6 M | 683.1 M |
| WAT | 2 M | 433 M | 461.4 M | 450 M | 431.6 M | 469.1 M | 521.5 M | 20.3 M | 593.8 M | 592.2 M | 521.6 M | 692.8 M | 707.8 M | 642.2 M | 637.8 M | 642.6 M | 373.6 M |
| CNC | (9.4 M) | 111.2 M | 2 M | 165.1 M | 271 M | 355 M | 562 M | 828 M | 900 M | 1.3 B | 1.8 B | 1.3 B | 1.2 B | 2.7 B | 3.3 B | (6.7 B) | (6.3 B) |
| SNN | 68.4 M | 582 M | 729 M | 556 M | 501 M | 410 M | 784 M | 767 M | 663 M | 600 M | 448 M | 524 M | 223 M | 263 M | 412 M | 473.8 M | 371.1 M |
| DGX | (626 M) | 470.6 M | 555.7 M | 849 M | 556 M | 709 M | 645 M | 772 M | 736 M | 858 M | 1.4 B | 2 B | 946 M | 854 M | 871 M | 992 M | 646.9 M |
| TEM | (115 M) | (115 M) | (115 M) | (115 M) | (115 M) | (115 M) | (115 M) | (115 M) | (115 M) | (115 M) | (209.9 M) | (259.2 M) | (289.8 M) | (214.1 M) | (705.8 M) | (635.2 M) | (603.5 M) |
| THC | 63 M | 82 M | 152 M | (134 M) | 12 M | (140 M) | (192 M) | (704 M) | 104 M | (215 M) | 399 M | 914 M | 411 M | 611 M | 3.2 B | 1.4 B | 1.5 B |
| WST | 15 M | 75.5 M | 80.7 M | 112.3 M | 127.1 M | 95.6 M | 143.6 M | 150.7 M | 206.9 M | 241.7 M | 346.2 M | 661.8 M | 585.9 M | 593.4 M | 492.7 M | 493.7 M | 518.4 M |
Medpace Holdings and related stocks such as Illumina, ICON PLC, and Hologic Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Medpace Holdings financial statement analysis. It represents the amount of money remaining after all of Medpace Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Medpace Holdings | MEDP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 5375 Medpace Way, |
| Exchange | NASDAQ Exchange |
USD 444.13
Additional Tools for Medpace Stock Analysis
When running Medpace Holdings' price analysis, check to measure Medpace Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medpace Holdings is operating at the current time. Most of Medpace Holdings' value examination focuses on studying past and present price action to predict the probability of Medpace Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medpace Holdings' price. Additionally, you may evaluate how the addition of Medpace Holdings to your portfolios can decrease your overall portfolio volatility.